TABLE 6

Status of Newborn Screening in the United States: Disorders Detected Secondary to Testing for Another Condition

StateSecondary-Target Conditionsa
Fatty Acid DisordersOrganic Acid DisordersAmino Acid DisordersOther Metabolic DisordersHbG, Variant Hemoglobins
CACTCPT-IaCPT- IIDE-REDGA-IIMCKATM/SCHADSC AD2M3HBA2MBG3MGACbl-C,DIBGMALARGBIOPT-BSBIOPT-RGCIT-IIH-PHEMETTYR- IITYR- IIIGALEGALK
AlabamaA
AlaskaBBBB
ArizonaA
ArkansasA
CaliforniaAA
ColoradoCCCCCCCCCCCCCCCCCCC
ConnecticutA
District of ColumbiaAAAAAA
DelawareAAAAA
FloridaA
GeorgiaBB
HawaiiBBBBA
IdahoBBBB
IllinoisA
IndianaA
IowaA
KansasA
KentuckyA
LouisianaA
MaineDDDDDDD
MarylandBBA
MassachusettsDDAAADDADAADAD
MichiganAAAAAAAAAAAAAAAA
Minnesota
MississippiAAAAAA
Missouri
MontanaBBBBBBBBBBBBBBBBBB
NebraskaAAAAAAAAAAAAA
NevadaBBBBA
New HampshireDB
New JerseyAAAAAAAAAAAA
New MexicoA
New York
North CarolinaA
North DakotaA
OhioA
OklahomaA
OregonAAAAAABBBB
PennsylvaniaBBBBBBBBBBBBBBBBBBBA
Rhode IslandD
South CarolinaA
South Dakota
Tennessee
TexasA
Utah
VermontDDDDDDDDDD
VirginiaA
WashingtonA
West VirginiaA
Wisconsin
Wyoming
  • A dot (•) indicates that screening for the condition is universally required by law or rule; A, universally offered but not yet required; B, offered to select populations or by request; C, testing is required but not yet implemented; D, likely to be detected (and reported) as a byproduct of multiple reaction monitoring screening (MS/MS) targeted by law or rule. 2M3HBA indicates 2-methyl-3-hydroxy butyric aciduria; 2MBG, 2-methylbutyryl-coenzyme A dehydrogenase; 3MGA, 3-methylglutaconic aciduria; ARG, argininemia (arginase deficiency); BIOPT-BS, defects of biopterin cofactor biosynthesis; BIOPT-REG, defects of biopterin cofactor regeneration; CACT, carnitine acylcarnitine translocase; CBL-C,D, methylmalonic acidemia (Cbl C,D); CIT-II, citrullinemia type II; CPT-Ia, carnitine palmitoyltransferase I; CPT-II, carnitine palmitoyltransferase II; De-Red, dienoyl-coenzyme A reductase; GA-II, glutaric academia type II; GALE, galactose epimerase; GALK, galactokinase; H-PHE, benign hyperphenylalaninemia; IBG, isobutyryl-coenzyme A dehydrogenase; M/SCHAD, medium/short-chain L-3-hydroxy acyl-coenzyme A dehydrogenase; MAL, malonic academia (malonyl-coenzyme A decarboxylase); MCKAT, medium-chain ketoacyl-coenzyme A thiolase; MET, hypermethioninemia; SCAD, short-chain acyl-coenzyme A dehydrogenase; TYR-II, tyrosinemia type II; TYR-III, tyrosinemia type III.

  • a Terminology is consistent with the American College of Medical Genetics. Newborn Screening: Toward a Uniform Screening Panel and System. Rockville, MD: Health Resources and Services Administration; 2005:63.

  • Nomenclature source: National Newborn Screening and Genetic Resource Center (http://genes-r-us.uthscsa.edu).